Zenas BioPharma Announces Closing of Full Exercise of Underwriters Option to Purchase Additional Shares in Initial Public Offering
| ZBIO Etf | USD 8.40 0.55 7.01% |
About 54% of Zenas BioPharma,'s investors are presently thinking to get in. The analysis of overall sentiment of trading Zenas BioPharma, Common etf suggests that some investors are interested at this time. Zenas BioPharma,'s investing sentiment overview a quick insight into current market opportunities from investing in Zenas BioPharma, Common. Many technical investors use Zenas BioPharma, Common etf news signals to limit their universe of possible portfolio assets and to time the market correctly.
Zenas |
WALTHAM, Mass., Sept. 19, 2024 -- Zenas BioPharma, Inc. , a clinical-stage global biopharmaceutical company...
Read at globenewswire.com
 |
Zenas BioPharma, Fundamental Analysis
We analyze Zenas BioPharma,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zenas BioPharma, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zenas BioPharma, based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
Zenas BioPharma, is rated below average in probability of bankruptcy as compared to similar ETFs. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
Zenas BioPharma, Common Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Zenas BioPharma, etf to make a market-neutral strategy. Peer analysis of Zenas BioPharma, could also be used in its relative valuation, which is a method of valuing Zenas BioPharma, by comparing valuation metrics with similar companies.
Peers
Zenas BioPharma, Related Equities
| ZBIO | Zenas BioPharma, | 7.01 | ||||
| MBOX | Freedom Day | 1.27 | ||||
| DHDG | FT Vest | 0.91 | ||||
| MBCC | Northern Lights | 0.72 | ||||
| MBBB | VanEck Vectors | 0.42 | ||||
| Z | Zillow Group | 0.28 | ||||
| MBNE | SSGA Active | 0.24 | ||||
| MBND | SPDR Nuveen | 0.15 |
Other Information on Investing in Zenas Etf
Zenas BioPharma, financial ratios help investors to determine whether Zenas Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zenas with respect to the benefits of owning Zenas BioPharma, security.